TSHA
NASDAQ · Biotechnology
Taysha Gene Therapies Inc
$5.02
-0.14 (-2.71%)
Open$5.16
Previous Close$5.16
Day High$5.28
Day Low$4.96
52W High$7.30
52W Low$2.71
Volume—
Avg Volume3.25M
Market Cap1.65B
P/E Ratio—
EPS$-0.41
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+1,112.4% upside
Current
$5.02
$5.02
Target
$60.86
$60.86
$45.99
$60.86 avg
$68.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 9.97M | 6.33M | 242.81M |
| Net Income | -111,076,659 | -63,460,288 | 41.01M |
| Profit Margin | -1,115.3% | -1,059.5% | 16.9% |
| EBITDA | -111,435,076 | -67,202,007 | 60.77M |
| Free Cash Flow | — | — | 46.40M |
| Rev Growth | +57.5% | +57.5% | -6.9% |
| Debt/Equity | 0.20 | 0.20 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |